Search Results
Feb 28, 2026, 13:07 ET Athletes from Sweden and the Netherlands Win Medals at the Olympic Winter Games Milano Cortina 2026 as Team TCL Ambassador Reaches the Podium
global leader in consumer electronics and the world's No. 1 Mini LED TV brand in the first half year of 2025, TCL unveiled its flagship SQD-Mini LED TV X11L at CES 2026, which won the Innovative Display Technology Gold Award for its exceptional color accuracy, display stability, and visual performance. With
More news about: TCL Europe
Feb 28, 2026, 12:41 ET CGTN: Con đường dân chủ của Trung Quốc bảo vệ quyền và lợi ích của người dân như thế nào
https://news.cgtn.com/news/2026-02-27/How-China-s-path-of-democracy-safeguards-people-s-rights-and-interests-1L6w4JWN8yI/p.html
More news about: CGTN
Feb 28, 2026, 12:37 ET CGTN: 중국의 민주주의 행보가 인민의 권익을 수호하는 방법
https://news.cgtn.com/news/2026-02-27/How-China-s-path-of-democracy-safeguards-people-s-rights-and-interests-1L6w4JWN8yI/p.html
More news about: CGTN
Feb 28, 2026, 11:00 ET PureHealth Research Launches "Natural GLP-1 Support" Collection, Delivering a Comprehensive Approach to Natural GLP-1 Supplements
Coffee Extract, the patented citrus flavonoid Eriomin®, and Akkermansia Muciniphila promote GLP-1 secretion from intestinal L-cells.
More news about: PureHealth Research LLC
Feb 28, 2026, 10:47 ET CGTN: How China's path of democracy safeguards people's rights and interests
https://news.cgtn.com/news/2026-02-27/How-China-s-path-of-democracy-safeguards-people-s-rights-and-interests-1L6w4JWN8yI/p.html
More news about: CGTN
Feb 27, 2026, 23:50 ET INVESTOR ALERT: NuScale Power Corporation Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
ENTRA1 was sufficiently experienced to own and operate the energy generation facilities contemplated by the TVA agreement. NuScale's CEO, defendant John L. Hopkins, further revealed during the call that the agreement between ENTRA1 and TVA contemplated as many as 72 NPMs, meaning NuScale's milestone payments
More news about: Robbins Geller Rudman & Dowd LLP
Feb 27, 2026, 23:08 ET CGTN: How China's path of democracy safeguards people's rights and interests
https://news.cgtn.com/news/2026-02-27/How-China-s-path-of-democracy-safeguards-people-s-rights-and-interests-1L6w4JWN8yI/p.html
More news about: CGTN
Feb 27, 2026, 20:00 ET U.S. Food and Drug Administration Approves BioMarin's PALYNZIQ® (pegvaliase-pqpz) for Adolescents 12 Years of Age and Older with Phenylketonuria (PKU)
guideline recommendations. Of those individuals, 75% were below 120 µmol/L and their average Phe reduction was 828 µmol/L (94% reduction in blood Phe from baseline). Nine participants whose blood Phe levels were below 30 µmol/L (hypophenylalaninemia) were able to increase their intact protein intake
More news about: BioMarin Pharmaceutical Inc.
Feb 27, 2026, 18:24 ET Globant Files Annual Report for 2025
hard copy of the Company's complete audited financial statements free of charge, by requesting a copy from: Globant S.A., 37A Avenue J.F. Kennedy, L-1855, Luxembourg.
More news about: Globant
Feb 27, 2026, 17:06 ET FLAGSTAR BANK, N.A. ANNOUNCES JUNE 9TH DATE FOR ITS 2026 ANNUAL MEETING OF SHAREHOLDERS
the payment of dividends on shares of our capital stock, including adjustments to the amount of dividends payable on shares of our preferred stock; (l) the availability of equity and dilution of existing equity holders associated with future equity awards and stock issuances; (m) the effects of the reverse
More news about: Flagstar Bank, National Association
Feb 27, 2026, 15:51 ET FDA approves Novo Nordisk's Sogroya® as the first and only once-weekly, long-acting growth hormone for three additional pediatric indications
hormone injection adherence and height among children with growth hormone deficiency. Endocr Pract. 2022;28:565-571.Brod M, Hojbjerre L, Alolga SL, et al. Understanding treatment burden for children treated for growth hormone deficiency. Patient. 2017;10:653-666.Johannson
More news about: Novo Nordisk
Feb 27, 2026, 13:31 ET Isaac Hayes Estate and Trump Campaign Resolve Music Lawsuit, Reaffirming Artist Rights
safeguarding dignity, value, and accountability for future generations.The Hayes family and Estate extend sincere gratitude to legal counsel James L. Walker Jr. and Brittney R. Dobbins, copyright administrator Liz Gamer, and the Walker and Associates team for their diligence, professionalism, and strategic
More news about: Isaac Hayes III
Feb 27, 2026, 12:36 ET BestQool's BQ60Pro: Next-Generation 6-Wavelength Home Red Light Therapy Device with Enhanced Output and Smarter Flexibility
Barolet D, Roberge CJ, Auger FA, Boucher A, Germain L. Regulation of Skin Collagen Metabolism In Vitro Using a Pulsed 660 nm LED Light Source: Clinical Correlation with a Single-Blinded Study. J Invest Dermatol.
More news about: Bestqool
Feb 27, 2026, 11:04 ET EQT exits remaining stake in Azelis Group
million STOCKHOLM, Feb. 27, 2026 /PRNewswire/ -- Akita I S. à r. L., an entity indirectly controlled by an affiliate of the EQT VIII fund ("EQT VIII") is pleased to announce the completion of the sale (the "Sale") of its
More news about: EQT
Feb 27, 2026, 11:00 ET Mopec Group Opens New Distribution Center as Part of Strategic Expansion of Michigan Manufacturing Operations
professionals around the world."The company commemorated the opening with a ribbon cutting event attended by state and local leaders, including Quentin L. Messer Jr., CEO of the Michigan Economic Development Corporation."This investment exemplifies the forward-thinking commitment we're proud to see
More news about: Mopec
Feb 27, 2026, 10:24 ET Sun Pharma Showcases Data Across its Dermatology & Immunology Portfolio at 2026 Winter Clinical Miami
color: 52-week extended follow-up analysisKircik L, Kircik A, et alEfficacy and safety of
More news about: Sun Pharma
Feb 27, 2026, 08:13 ET Metanoia社がAI駆動型5G向けのオープンSDRプラットフォームをMWC 2026で発表し、急成長するオープンRANをさらに加速
スペイン、バルセロナ、2026年2月27日/PRNewswire/ -- MWC 2026（第5ホール、5L24MR & 5L26MR） - Metanoia社は本日、商業の勢いを加速させる同社のMT2824「Cobra」5G SoCおよびMOSART Open Foundation Software Defined Radio（SDR）プラットフォームを発表し、FR1およびFR2無線インフラの経済性を再定義しました。
More news about: Metanoia Communications Inc.
Feb 27, 2026, 07:38 ET Metanoia zündet auf dem MWC 2026 mit einer offenen SDR-Plattform für KI-gesteuertes 5G den Umbruch im Open RAN
BARCELONA, Spanien, 27. Februar 2026 /PRNewswire/ -- MWC 2026 (Halle 5, 5L24MR & 5L26MR) – Metanoia präsentierte heute deutliche kommerzielle Fortschritte rund um sein 5G-SoC MT2824 „Cobra" sowie die MOSART Open Foundation Software
More news about: Metanoia Communications Inc.
Feb 27, 2026, 07:38 ET Metanoia annonce la disruption de l'Open RAN au MWC 2026 avec une plateforme SDR ouverte pour la 5G pilotée par l'IA
BARCELONE, Espagne, 27 février 2026 /PRNewswire/ -- MWC 2026 (Hall 5, 5L24MR et 5L26MR) - Metanoia a dévoilé aujourd'hui une dynamique commerciale majeure avec son MT2824 « Cobra » 5G SoC et sa plateforme de radio logicielle
More news about: Metanoia Communications Inc.
Feb 27, 2026, 07:01 ET Norgine welcomes positive CHMP opinion recommending approval of mavorixafor in the European Union for WHIM syndrome
WHIM Syndrome - Symptoms, Causes, Treatment | NORD, accessed February 2026[3] Badolato R, Alsina L, Azar A, et al. A phase 3 randomized trial of mavorixafor, a CXCR4 antagonist, for WHIM syndrome. Blood. 2024;144(1):35‑45.Logo -
More news about: Norgine
Feb 27, 2026, 07:01 ET Norgine welcomes positive CHMP opinion recommending approval of mavorixafor in the European Union for WHIM syndrome
WHIM Syndrome - Symptoms, Causes, Treatment | NORD, accessed February 2026[3] Badolato R, Alsina L, Azar A, et al. A phase 3 randomized trial of mavorixafor, a CXCR4 antagonist, for WHIM syndrome. Blood. 2024;144(1):35‑45.Logo -
More news about: Norgine
Feb 27, 2026, 07:01 ET Norgine begrüßt positive CHMP-Stellungnahme, die die Zulassung von Mavorixafor in der Europäischen Union für das WHIM-Syndrom empfiehlt
WHIM-Syndrom - Symptome, Ursachen, Behandlung | NORD, Zugriff im Februar 2026[3] Badolato R, Alsina L, Azar A, et al. A phase 3 randomized trial of mavorixafor, a CXCR4 antagonist, for WHIM syndrome. Blut. 2024;144(1):35-45.Logo -
More news about: Norgine
Feb 27, 2026, 07:01 ET Norgine celebra la opinión positiva del CHMP que recomienda la aprobación de mavorixafor
WHIM Syndrome - Symptoms, Causes, Treatment | NORD, consultado en febrero de 2026[3] Badolato R, Alsina L, Azar A, et al. A phase 3 randomized trial of mavorixafor, a CXCR4 antagonist, for WHIM syndrome. Blood. 2024;144(1):35–45.Logo -
More news about: Norgine
Feb 27, 2026, 07:01 ET Norgine se félicite de l'avis positif du CHMP recommandant l'approbation du mavorixafor dans l'Union européenne pour le syndrome WHIM
WHIM Syndrome - Symptômes, causes, traitement | NORD, consulté en février 2026[3] Badolato R, Alsina L, Azar A, et al. A phase 3 randomized trial of mavorixafor, a CXCR4 antagonist, for WHIM syndrome. Sang. 2024;144(1):35-45.Logo -
More news about: Norgine
Feb 27, 2026, 07:00 ET Calumet Reports Fourth Quarter and Fiscal Year 2025 Results
the impact of liquidation of inventory layers calculated using the LIFO method; (j) RINs mark-to-market adjustments; (k) RINs incurrence expense; and (l) all extraordinary, unusual or non-recurring items of gain or loss, or revenue or expense.We define Adjusted EBITDA with Tax Attributes for any
More news about: Calumet, Inc.